Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study

Authors

C. Fountzilas, Roswell Park Comprehensive Cancer Center, NY
A.H. Ko, University of California at San Francisco
E.H. Borazanci, HonorHealth Research Institute, AZ
J.T. D'Olimpio, Clinical Research Alliance, NY
J.R. Hecht, University of California at Los Angeles
Shou-Ching Tang, LSU Health Sciences Center - New OrleansFollow
A.F. Shields, Wayne State University, MI
M.A. Salkeni, Virginia Cancer Specialists Research Institute
G.C. Michelson, CG Pharmaceuticals Inc.
L. Liganor, CG Pharmaceuticals Inc.
G. Cho, CG Pharmaceuticals Inc.
S.A. Cho, CG Pharmaceuticals Inc.
E.J. Walker, University of California at San Francisco

Document Type

Conference Proceeding

Publication Date

1-27-2025

Publication Title

Journal of Clinical Oncology (2025) 43 Supplement 4. Date of Publication: 1 Feb 2025

Abstract

2025 ASCO Gastrointestinal Cancers Symposium, January 23 - 25, 2025, San Francisco, CA

Volume

43

Comments

Abstract 742

Recommended Citation

Fountzilas, C.; Ko, A.H.; Borazanci, E.H.; D'Olimpio, J.T.; Hecht, J.R.; Tang, Shou-Ching; Shields, A.F.; Salkeni, M.A.; Michelson, G.C.; Liganor, L.; Cho, G.; Cho, S.A.; and Walker, E.J., "Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study" (2025). School of Medicine Faculty Publications. 3710.
https://digitalscholar.lsuhsc.edu/som_facpubs/3710
10.1200/JCO.2025.43.4_suppl.742